STEVENSON, Md., May 15, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A
Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the
Southern District of New York on behalf of purchasers of Akari Therapeutics, Plc (Nasdaq:AKTX) (“Akari” or the “Company”)
securities during the period between March 30, 2017 and May 11, 2017, inclusive (the “Class Period”). Investors who wish to
become proactively involved in the litigation have until July 11, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and
be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including
whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants
claiming the largest loss from investment in Akari securities during the Class Period. Members of the class will be
represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above
action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the
defendants’ failure to disclose during the Class Period that Dr. Gur Roshwalb (“Roshwalb”), the Company's Chief Executive Officer
(“CEO”), and possibly other executives, were involved in publishing false information about the Company, including false
information about the Phase 2 PNH trial of Coversin and that the Company lacked adequate checks and protections to prevent such
behavior.
According to the complaint, following a May 11, 2017 announcement that Roshwalb was placed on administrative
leave while the Board of Directors investigates the involvement of Company personnel in connection with a report issued on April
26, 2017, the value of Akari shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Akari securities purchased on or after
March 30, 2017 and held through the revelation of negative information during and/or at the end of the Class Period and would like
to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please
visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may
also request more information by contacting Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410)
415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question
to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and
have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower
Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at
this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 hoffman@browerpiven.com
